Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 16/20 | 0.80 |
| ▸ | MAPK13 | O15264 | 15/20 | 0.80 |
| ▸ | MAPK12 | P53778 | 15/20 | 0.80 |
| ▸ | MAPK11 | Q15759 | 15/20 | 0.80 |
| ▸ | RECQL | P46063 | 1/20 | 0.51 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7211089 | 0.91 | MAPK14 (0.80) | MAPK14MAPK13MAPK12MAPK11RECQL | |
| SCHEMBL7199757 | 0.90 | MAPK14 (0.79) | MAPK14MAPK13MAPK12MAPK11RECQL | |
| SCHEMBL2201099 | 0.89 | MAPK14 (1.00) | MAPK14MAPK13MAPK12MAPK11MAPT | |
| SCHEMBL6394890 | 0.89 | MAPK14 (0.84) | MAPK14MAPK13MAPK12MAPK11RECQL | |
| SCHEMBL1907242 | 0.87 | MAPK14 (0.81) | MAPK14MAPK13MAPK12MAPK11KDM4E | |
| SCHEMBL7194273 | 0.87 | MAPK14 (0.74) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL1904637 | 0.84 | MAPK14 (1.00) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL1907736 | 0.84 | MAPK14 (0.87) | MAPK14MAPK13MAPK12MAPK11KDM4E | |
| SCHEMBL6655830 | 0.84 | MAPK14 (0.80) | MAPK14MAPK13MAPK12MAPK11KDM4E | |
| SCHEMBL1906421 | 0.83 | MAPK14 (0.87) | MAPK14MAPK13MAPK12MAPK11MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1202954-B1 | NOVEL AMINOBENZOPHENONES | LEO PHARMA AS (DK) | 2003-10-01 | — | — | EP | claimed |
| US-6624199-B1 | Prophylaxis and treatment of acne and acne related skin diseases with aminobenzophenones, and novel compounds effective in the treatment, as well as pharmaceutical preparations containing these compounds and dosage units | LEO PHARMACEUTICALS PRODUCTS LTD. A/S (DK) | 2003-09-23 | — | — | US | claimed |
| US-20020165286-A1 | Dermal anti-inflammatory composition | LEO PHARMACEUTICAL PRODUCTS LTD. A/S (DK) | 2002-11-07 | — | — | US | claimed |
| EP-1202954-A1 | NOVEL AMINOBENZOPHENONES | LEO PHARMACEUTICAL PRODUCTS LTD. A/S (LOVENS KEMISKE FABRIK PRODUKTIONSAKTIESELSKAB) (DK) | 2002-05-08 | — | — | EP | claimed |
| WO-2001005744-A1 | NOVEL AMINOBENZOPHENONES | Leo Pharmaceutical Products Ltd. A/S (Løvens Kemiske Fabrik Produktionsaktieselskab) (DK) | 2001-01-25 | — | — | WO | claimed |
| EP-1202954-B1 | NOVEL AMINOBENZOPHENONES | LEO PHARMA AS (DK) | 2003-10-01 | — | — | EP | disclosed |
| US-6624199-B1 | Prophylaxis and treatment of acne and acne related skin diseases with aminobenzophenones, and novel compounds effective in the treatment, as well as pharmaceutical preparations containing these compounds and dosage units | LEO PHARMACEUTICALS PRODUCTS LTD. A/S (DK) | 2003-09-23 | — | — | US | disclosed |
| US-20020165286-A1 | Dermal anti-inflammatory composition | LEO PHARMACEUTICAL PRODUCTS LTD. A/S (DK) | 2002-11-07 | — | — | US | disclosed |
| WO-2002045752-A2 | DERMAL ANTI-INFLAMMATORY COMPOSITION | LEO PHARMA A/S (DK) | 2002-06-13 | — | — | WO | disclosed |
| EP-1202954-A1 | NOVEL AMINOBENZOPHENONES | LEO PHARMACEUTICAL PRODUCTS LTD. A/S (LOVENS KEMISKE FABRIK PRODUKTIONSAKTIESELSKAB) (DK) | 2002-05-08 | — | — | EP | disclosed |
| WO-2001005744-A1 | NOVEL AMINOBENZOPHENONES | Leo Pharmaceutical Products Ltd. A/S (Løvens Kemiske Fabrik Produktionsaktieselskab) (DK) | 2001-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020165286-A1 | Dermal anti-inflammatory composition | CUTA, IL1B, LRBA | MAPK14 644/4885MAPK13 1521/4885MAPK12 1535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.